WHEN IS CHEMOTHERAPY AN APPROPRIATE TREATMENT CHOICE IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)?1,2

  • Triple negative breast cancer (TNBC)
  • Hormone receptor (HR) + and hormone refractory/resistant disease
  • Visceral metastases
When selecting chemotherapy in patients with MBC, what characteristics or poor prognostic factors are considered?
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL